TABLE 2.

Stage IV Treatment Characteristics, N = 81

	No. of Patients (%)
Treatment Characteristic	Germline BRCA Cohort	Somatic BRCA Cohort
No of treatment lines	gBRCA, n = 69	sBRCA, n = 12
Median [range]	2 [0-6]	3 [0-5]
Frontline chemotherapy	gBRCA, n = 69	sBRCA, n = 12
Platinum	58 (84)	7 (58)
Gemcitabine and Nab-paclitaxel	8 (12)	4 (33)
Gemcitabine combination, other	2 (3)	–
None	1 (1)	1 (8)
Frontline nonplatinum duration, mo	gBRCA	sBRCA
Median [range]	6 [2-51]	8 [3-40]
Frontline platinum duration, mo	gBRCA	sBRCA
Median [range]	9 [1-31]	10 [2-11]
Frontline platinum	gBRCA, n = 58	sBRCA, n = 7
Oxaliplatin	33 (57)	7 (100)
Cisplatin	25 (43)	0 (0)
Frontline platinum best overall response	gBRCA, n = 58	sBRCA, n = 7
PR	46 (80)	6 (86)
SD	6 (10)	–
POD	6 (10)	1 (14)
Frontline oxaliplatin best overall response	gBRCA, n = 33	sBRCA, n = 7
PR	28 (85)	6 (86)
SD	2 (6)	–
POD	3 (9)	1 (14)
Frontline cisplatin best overall response	gBRCA, n = 25	sBRCA, n = 0
PR	18 (72)	–
SD	4 (16)	–
POD	3 (12)	–
Platinum therapy, any line	gBRCA n = 69	sBRCA, n = 12
Yes	66 (96)	10 (83)
Best overall response to platinum therapy, any line	gBRCA, n = 66	sBRCA, n = 10
PR	50 (76)	9 (90)
SD	7 (10)	–
POD	9 (14)	1 (10)
Frontline nonplatinum best overall response	gBRCA, n = 10	sBRCA, n = 4
PR	7 (70)	1 (25)
SD	–	2 (50)
POD	3 (30)	1 (25)

Abbreviations: gBRCA, germline BRCA mutation; sBRCA, somatic BRCA mutation; Nab-paclitaxel, -bound paclitaxel; POD, progression of disease; PR, partial response; SD, stable disease.